226-240 of 894
Charles Turck, PharmD, BCPS, BCCCP
Jamie Koprivnikar, MD
Abdulraheem Yacoub, MD
Understanding the Role of the Alternate Complement Pathway in PNH
Project Oncology®Understanding the Role of the Alternate Complement Pathway in PNH
Jennifer Caudle, DO, FACOFP
Catherine Broome, MD
Recognizing the Burden of Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®Recognizing the Burden of Paroxysmal Nocturnal Hemoglobinuria
Brian P. McDonough, MD, FAAFP
Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Brian P. McDonough, MD, FAAFP
Charles Turck, PharmD, BCPS, BCCCP
Hana Safah, MD
Timothy Kubal, MD
Charles Turck, PharmD, BCPS, BCCCP
David Dingli, MD, PhD
- advertisement
Examining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®Examining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
Charles Turck, PharmD, BCPS, BCCCP
Brian Mulherin, MD
Managing PNH Patients: Addressing the Unmet Needs
Project Oncology®Managing PNH Patients: Addressing the Unmet Needs
Charles Turck, PharmD, BCPS, BCCCP
Brian Mulherin, MD
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart MattersNavigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Jun-ichi Abe
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Project Oncology®10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Ryan Quigley
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
- advertisement
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Project Oncology®Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Project Oncology®Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Project Oncology®Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Jennifer Caudle, DO, FACOFP
Samuel Klempner, MD
Nataliya Uboha, MD, PhD
